A molecular profiling study of patients with EGFR mutation-positive locally advanced or metastatic NSCLC treated with osimertinib

Trial Identifier: D5161C00003
Sponsor: AstraZeneca
Collaborator:
PAREXEL
NCTID:: NCT03239340
Start Date: May 2018
Primary Completion Date: September 2023
Study Completion Date: September 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations